Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Defining a role for laquinimod in multiple sclerosis - Bernd C. Kieseier, 2014
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Active Biotech Regains Rights to Laquinimod from Teva, Plans to Continue Work on Potential MS Oral Therapy
FDA Marks Change in Clinical Test Dose of MS Therapy, Laquinimod
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod - Wikipedia
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
Teva reaches $925,000 settlement to resolve drug price-fixing claims - PMLiVE
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Teva Pharmaceuticals - Wikipedia
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Teva Completes Enrollment in Laquinimod Phase III Clinical Trial - Recruitment Still Ongoing For Second, Pivotal Phase III Study
Laquinimod senkt Schubrate und Progressionsrisiko - 06 - 2012 - Heftarchiv - AMT
Laquinimod - an overview | ScienceDirect Topics
EuroBiotech Report—Teva dumps laquinimod, Gilead-Galapagos, GV-Evox, Abivax data and ProQR | Fierce Biotech
Laquinimod - an overview | ScienceDirect Topics
